BioPlus Acquisition Corp. (BIOSW)

BioPlus Acquisition Corp. (BIOSW) — VMCI valuation read

BIOSW prints VMCI 39/100 inside the Financial Services sector, where the median sits at 50. The 11-point below-median delta is the cleanest single-number summary of BioPlus Acquisition Corp.'s composite stance, and in the mid-cap bucket it places the share behind the typical peer on the five-pillar mix.

On BIOSW, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** BIOSW trades at 20.0x earnings, 11% above the Financial Services median of 18.0x; that is the value line. ROIC of 14.0% sits 4.0pp above the Financial Services median (10.0%); that is the quality line. net debt to EBITDA of 2.2x is the rate-sensitivity line to watch; that is the risk line for BioPlus Acquisition Corp. on the trailing financials.

BIOSW fell 3.0% over the trailing 7 days, with a +6.8% read on a 30-day basis.